BEGIN:VCALENDAR
PRODID:-//planitpurple.northwestern.edu//iCalendar Event//EN
VERSION:2.0
CALSCALE:GREGORIAN
METHOD:PUBLISH
CLASS:PUBLIC
BEGIN:VTIMEZONE
TZID:America/Chicago
TZURL:http://tzurl.org/zoneinfo-outlook/America/Chicago
X-LIC-LOCATION:America/Chicago
BEGIN:DAYLIGHT
TZOFFSETFROM:-0600
TZOFFSETTO:-0500
TZNAME:CDT
DTSTART:19700308T020000
RRULE:FREQ=YEARLY;BYMONTH=3;BYDAY=2SU
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0500
TZOFFSETTO:-0600
TZNAME:CST
DTSTART:19701101T020000
RRULE:FREQ=YEARLY;BYMONTH=11;BYDAY=1SU
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
SEQUENCE:0
DTSTART;TZID=America/Chicago:20251211T100000
DTEND;TZID=America/Chicago:20251211T110000
DTSTAMP:20260808T063806Z
SUMMARY:BMG Seminar: Matthew G. Oser MD\, PhD\, Harvard Medical School
UID:633731@northwestern.edu
TZID:America/Chicago
DESCRIPTION:The Department of Biochemistry & Molecular Genetics presents:  Matthew G. Oser MD\, PhD Department of Medical Oncology\, Division of Molecular and Cellular Oncology Assistant Professor\, Dana-Farber Cancer Institute\, Harvard Medical School  Presentation:   Innovative Therapeutic Strategies for Small Cell Lung Cancer: From Genomic Vulnerabilities to Lineage Plasticity  Small cell lung cancer (SCLC) is characterized by near-universal loss of RB1 and TP53 and by molecular subtypes driven by lineage transcription factors\, yet effective therapeutic strategies remain limited. In this talk\, I will highlight three examples from my lab where CRISPR-based functional genomics has uncovered new therapeutic opportunities in SCLC. First\, I will discuss the discovery of cyclin A/B RxL inhibition as a novel therapeutic strategy that exploits the core genomic vulnerability created by RB1 and TP53 loss in SCLC\, with broader applicability to cancers harboring mutations that compromise the G1-S checkpoint. Second\, I will describe how the use of endogenous knock-in reporters of lineage transcription factor dependencies in SCLC\, coupled with genome-wide CRISPR screening\, can reveal novel potential therapeutic strategies. Third\, I will present how CRISPR-based somatic gene editing in mouse models of SCLC identified EED\, as part of the PRC2 complex\, as essential to maintain the SCLC neuroendocrine tumor cell state\, thereby revealing EED as a potential therapeutic target to block lung adenocarcinoma-to-SCLC transformation\, a mechanism of acquired resistance to targeted therapies in lung adenocarcinoma. Together\, these examples showcase how targeting genomic vulnerabilities\, lineage transcription factor dependencies\, and lineage plasticity can open new avenues for precision therapy in SCLC.  Host: Dr. Lu Wang\, Assistant Professor\, Biochemistry and Molecular Genetics  Refreshments will be served.
LOCATION:Robert H Lurie Medical Research Center\, Baldwin Auditorium\, 303 E. Superior\, Chicago\, IL 60611
TRANSP:OPAQUE
URL:https://planitpurple.northwestern.edu/event/633731
CREATED:20220725T050000Z
STATUS:CONFIRMED
LAST-MODIFIED:20251210T203035Z
PRIORITY:0
BEGIN:VALARM
TRIGGER:-PT10M
ACTION:DISPLAY
DESCRIPTION:Reminder
END:VALARM
END:VEVENT
END:VCALENDAR